Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Salmonella guidance

This article was originally published in The Tan Sheet

Executive Summary

FDA publishes draft guidance addressing the risk of salmonella contamination in pistachio-derived ingredients. The agency will accept comments on the guidance until Aug. 28, according to a June 29 Federal Register notice. FDA published a guidance on avoiding salmonella contamination of peanut products in March (1"The Tan Sheet" March 16, 2009, In Brief)

You may also be interested in...



Guidance for salmonella in peanut products

FDA issues guidance to assist manufacturers of products containing peanut ingredients in avoiding contamination by salmonella bacteria. The March 11 guidance advises firms to "obtain peanut-derived product only from suppliers with validated processes in place to adequately reduce the presence of salmonella." FDA suggests companies not rely on a history of negative microbiological tests for salmonella in finished peanut product, as this does not ensure the adequacy of a supplier's procedures for controlling bacteria. Peanut-containing products recalled recently in the salmonella outbreak include nutritional bars, though industry experts say dietary supplement ingredients generally do not harbor harmful bacteria (1"The Tan Sheet" Jan. 26, 2009, p. 8)

Probiotics And Cold Remedies Boost Recordati In 2023

Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.

Falling Sales Force New Priorities At Roche

The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel